




Experimental or Off-Label Drug/Therapy/Device Disclosure

I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA.


<section-header><list-item><list-item><list-item><list-item>





















































Dosing Inf GLP-1 RA	ormation and GIP/GI	_P-1 RA	Indication	23
Liraglutide (Victo	,		Diabetes	
Liraglutide (Saxe	enda) 0.6, 1.2, 1.8 3.0	mg SQ daliy	Weight Loss	
Dulaglutide (Tru	licity) 0.75, 1.5 mg SC	Qweekly	Diabetes	
Dulaglutide (Tru	licity) 3.0, 4.5 mg SQ	weekly	Diabetes	
 Semaglutide (Ry 	/belsus) 3, 7, 14 mg po c	laily	Diabetes	
Semaglutide (Oz		-	Diabetes	
Semaglutide (Oz	zempic) 0.25, 0.5, 1.0, 2	.0 mg SQ weekly	Diabetes	
Semaglutide (W	egovy) 0.25, 0.5, 1.0, 1	.7, 2.4 mg SQ weekly	Weight Loss	
Tirzepatide (Mou	unjaro) 2.5, 5, 7.5, 10, 1	I2.5, 15 mg SQ weekly	Diabetes	
Victoza, Saxenda, Trulicity, Rybelsus, Ozempic, Wegovy, Mounjaro [prescribing information].				













































Tirzepatide: SURMOUNT-1 The New ENGLAND JOURNAL of MEDICINE 35
ORIGINAL ARTICLE
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C. Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D., for the SURMOUNT-1 Investigators*
 <u>Objective</u>: To investigate the efficacy and safety of tirzepatide vs placebo for weight management in adults with overweight or obesity but <u>without type 2 diabetes</u>
 <u>Design</u>: 72-week randomized, double-blind, placebo-controlled trial
 BMI ≥30 or ≥27 with at least 1 weight-related complication, age ≥18, without diabetes
• 4 arms: tirzepatide 5 mg, 10 mg, 15 mg, or placebo
 <u>Primary Outcomes</u>: % change in body weight, proportion of participants losing 5% at 72 weeks; <u>Secondary</u>: participants losing 10%, 15% or 20% of baseline weight at week 72
Jastreboff AM. N Engl J Med 2022; 387:205-216.




























Oral Semaglutide: OASIS-1


Weight Loss Trial

- <u>Objective</u>: To investigate the efficacy, safety, and tolerability of high-dose (25, 50 mg) oral semaglutide vs standard dose oral semaglutide (7, 14 mg) placebo in overweight adults with T2DM
- · Design: 68-week randomized, double-blind, placebo-controlled phase 3 superiority trial
 - BMI ≥30 or , ≥27 with bodyweight-related complications/comorbidities, age ≥18, without T2DM
 - · Randomized to placebo or oral semaglutide escalated to 50 mg daily
- <u>Primary Outcomes</u>: % change in body weight and proportion of participants achieving ≥5% bodyweight 68 weeks
- Results:
 - Percent bodyweight change: 50 mg = 15.1% vs placebo = 2.4% (p<0.0001)
 - · Percent achieving target bodyweight loss:
 - ≥5% = 85% vs 26%; OR 12.6, 8.5-18.7; p<0.0001
 - ≥10% = 69% vs 12%; OR 14.7, 9.6-22.6
 - ≥15% = 54% vs 6%; OR 17.9, 10.4-30.7
 - ≥20% = 34% vs 3%; OR 18.5, 8.8-38.9


Knop FK. Lancet. 2023; 402(10403);705-719.











Orforglipron – Obesity Trial 49
ORIGINAL ARTICLE
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, M.D., Thomas Blevins, M.D., Lisa Connery, M.D., Julio Rosenstock, M.D., Sohini Raha, Ph.D., Rong Liu, Ph.D., Xiaosu Ma, Ph.D., Kieren J. Mather, M.D., Axel Haupt, M.D., Deborah Robins, M.S., Edward Pratt, M.D., Christof Kazda, M.D., and Manige Konig, M.D., Ph.D., for the GZGI Investigators*
 <u>Objective</u>: To evaluate the efficacy and safety of orforglipron in adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes
Design: Phase 2, randomized, double-blind trial
Orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks
 Primary End Points: The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point)
Wharton S. N Engl J Med. 2023 published online. DOI: 10.1056/NEJMoa2302392
































































References

- 1. https://www.cdc.gov/obesity. Accessed 3/12/2023.
- Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files— Development of files and prevalence estimates for selected health outcomes. National Health Statistics Reports; no 158. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://dx.doi. org/10.15620/cdc:106273.
- Grunvald E, Shah R, Hernaez R. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology 2022;163:1198-1225.
- Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 Mar;6(3):237-248. doi: 10.1016/S2213-8587(17)30236-X.
- Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016 May 7;387(10031):1947-56. doi: 10.1016/S0140-6736(16)00271-3.
 Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602.
- Alexis V. Fanshier, Brianne K. Crews, Madison C. Garrett, Jeremy L. Johnson; Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes—The First Twincretin. Clin Diabetes 2023; cd220060. <u>https://doi.org/10.2337/cd22-0060</u>.
- 8. Victoza (liraglutide) package insert. Princeton, NJ: Novo Nordisk Inc; 2022 Jun.
- 9. Saxenda (liraglutide) injection package insert. Plainsboro, NJ: Novo Nordisk Inc; 2020 Dec
- 10. Trulicity (dulaglutide) package insert. Indianapolis, IN: Eli Lilly and Company; 2022 Dec
- Rybelsus (semaglutide) package insert. Plainsboro, NJ: Novo Nordisk Inc; 2023 Jan.
 Ozempic (semaglutide) package insert. Plainsboro, NJ: Novo Nordisk Inc: 2022 Oct.
- Ozempic (semaglutide) package insert. Plainsboro, NJ: Novo Nordisk Inc: 2022 Oc
 Wegovy (semaglutide) package insert. Plainsboro, NJ: Novo Nordisk Inc; 2023 Jan
- Megory (semagidide) package insert. Plansbolo, No. Noto Norolask inc, 2023 Jan.
 Mounjaro (tirzepatide) package insert. Indianapolis, IN: Eli Lilly and Company; 2022 Sep.
- Davies MJ, Bergenstal R, Bode B. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699.
- Sunyer XP, Astrup A, Fujioka K. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11-22.
 Frias JP, Bonora E, Ruiz LN. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)Diabetes Care. 2021;44:765–773.
- Rubino D, Abrahamsson N, Davies M. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
- Jastrebolf AM, Aronne LJ, Ahmad NN. Tirepatide Once Weekly for Treatment of Obesity. N Engl J Med 2022; 387:205-216.
- 20. https://diabetes.medicinematters.com/tirzepatide/type-2-diabetes/a-quick-quide-to-the-surpass-and-surmount-trials/18478154. Accessed 3/12/2023

